ADC Therapeutics (ADCT) Operating Margin: 2019-2023
Historic Operating Margin for ADC Therapeutics (ADCT) over the last 4 years, with Sep 2023 value amounting to -249.42%.
- ADC Therapeutics' Operating Margin fell 24534.00% to -249.42% in Q3 2023 from the same period last year, while for Sep 2023 it was -241.08%, marking a year-over-year decrease of 16047.00%. This contributed to the annual value of -58.90% for FY2022, which is 71275.00% up from last year.
- Per ADC Therapeutics' latest filing, its Operating Margin stood at -249.42% for Q3 2023, which was down 21.31% from -205.62% recorded in Q2 2023.
- ADC Therapeutics' Operating Margin's 5-year high stood at 1,361.82% during Q1 2021, with a 5-year trough of -162,315.79% in Q3 2020.
- Its 3-year average for Operating Margin is -232.33%, with a median of -249.42% in 2023.
- In the last 5 years, ADC Therapeutics' Operating Margin slumped by 16,231,579bps in 2020 and then spiked by 16,187,621bps in 2021.
- ADC Therapeutics' Operating Margin (Quarterly) stood at 0.00% in 2019, then slumped by 16,231,579bps to -162,315.79% in 2020, then skyrocketed by 16,187,621bps to -369.08% in 2021, then skyrocketed by 35,370bps to -15.38% in 2022, then slumped by 24,534bps to -249.42% in 2023.
- Its last three reported values are -249.42% in Q3 2023, -205.62% for Q2 2023, and -271.55% during Q1 2023.